You are viewing the site in preview mode

Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Doxycycline-induced photosensitivity in patients treated for erythema migrans

  • 1,
  • 2, 3,
  • 1 and
  • 1, 3Email author
BMC Infectious Diseases201818:365

https://doi.org/10.1186/s12879-018-3270-y

  • Received: 17 January 2018
  • Accepted: 25 July 2018
  • Published:
Open Peer Review reports

Abstract

Background

Doxycycline is one of the recommended antibiotics for treating erythema migrans (EM). Since EM predominantly occurs during summer, the potential of doxycycline to induce photosensitivity is of concern. In studies on the efficacy of doxycycline for treating relatively small numbers of patients with EM, the reported frequency of photosensitivity has varied from none to 15%. The aim of this study was to elucidate the frequency and clinical symptoms of doxycycline-induced photosensitivity in a large cohort of patients with EM treated in a single medical centre.

Methods

Prospectively collected data on adverse events were analysed in adult patients with EM treated with doxycycline 100 mg twice daily for 10–15 days.

Results

Photosensitivity reactions ranging from itching and burning sensations to transient mild erythema of sun-exposed skin were documented in 16/858 (1.9, 95% CI 1.1–3.0%) patients and appeared from June to October with highest frequency in July. These adverse events were more frequent in patients treated for 14 or 15 days (16/750 [2.1%]; 95% CI 1.2–3.4%) than in those treated for 10 days (0/108 [0%]; 95% CI 0.0–3.4%); however, the difference was not significant (P = 0.24). Women were more often affected than men (13/475 [2.7%], 95% CI 1.5–4.6% versus 3/383 [0.8%], 95% CI 0.2–2.3%; P = 0.04). Of the 16 patients who developed photosensitivity, 13 did not adhere to the recommendation to avoid sun exposure. None of the patients had any long-term sequelae of photosensitivity.

Conclusions

Photosensitivity reactions in adult patients with EM treated with doxycycline 100 mg twice daily for 10–15 days occurred rarely, were not severe, and had no long-term sequelae.

Trial registration

Registered at http://clinicaltrials.gov, Identifiers NCT00910715, May 28th 2009, NCT01163994, July 13th 2010 and NCT03584919, June 19th 2018 retrospectively registered.

Keywords

  • Doxycycline
  • Photosensitivity
  • Erythema migrans
  • Tick-borne disease

Background

Erythema migrans (EM) is the most frequent manifestation of Lyme borreliosis [1]. In addition to amoxicillin and cefuroxime axetil, oral doxycycline is a recommended treatment regimen for adult patients with EM [2]. Doxycycline has the advantage of its efficacy against Anaplasma phagocytophilum, the possible coinfecting bacterium in patients with early Lyme borreliosis [2], but its major drawback is potential photosensitization [3, 4], which is of particular concern because EM predominantly occurs during summer. Patients with EM who are prescribed doxycycline are therefore advised to avoid exposure to the sun while receiving therapy [2].

In studies on the treatment efficacy of doxycycline in patients with EM, reported photosensitivity ranged from none (0/108) to 15% (9/60) (Table 1) [314]. The reasons for this wide range are not clear and cannot be explained solely by variations in treatment duration or dosing of doxycycline in different treatment trials (Table 1). Variations in the advice to patients on sun restriction and in monitoring adverse events at different centres may be implicated. Further, the relatively small numbers of patients evaluated in individual trials probably also contributes to such pronounced disparities. In these studies, clinical symptoms of photosensitivity were not described. According to a recent review they can vary from a light sunburn-like sensation (burning, erythema) to large-area photodermatitis, and even onycholysis [15].
Table 1

Data on photosensitivity in doxycycline-treated patients with erythema migrans in Europe (Eu) and the United States (US)

First author, year

Eu/ US

Number of patients (% of female)

Doxycycline

Patients (%) with photosensitivity

Dosage

Days

Dattwyler, 1990 [7]

US

37 (49%)

100 mg twice daily

21

1 (2.7%)

Nadelman, 1992 [4]

US

60 (42%)

100 mg three times daily

20

9 (15%)

Massarotti, 1992 [8]

US

22 (50%)

100 mg twice daily

10–20

1 (4.5%)

Strle, 1992 [13]

Eu

23 (57%)

100 mg twice daily

14

1 (4.3%)

Strle, 1993 [11]

Eu

52 (44%)

100 mg twice daily

14

6 (11.5%)

Luger, 1995 [3]

US

113 (37%)

100 mg three times daily

12–20

7 (6.2%)

Strle, 1996 [12]

Eu

42 (50%)

100 mg twice daily

14

5 (11.9%)

Dattwyler, 1997 [6]

US

72 (39%)

100 mg twice daily

21

9 (12%)

Baršić, 2000 [10]

Eu

40 (52%)

100 mg twice daily

14

0

Wormser, 2003 [5]

US

61 (32%)

100 mg twice daily

10

5 (8.2%)

59 (40%)

20

2 (3.4%)

Cerar, 2010 [9]

Eu

145 (58%)

100 mg twice daily

15

1 (0.7%)

Stupica, 2012 [14]

Eu

108 (57%)

100 mg twice daily

10

0

117 (54%)

15

7 (6%)

The aim of the present study was to analyse prospectively collected data on the frequency and intensity of photosensitivity reactions in a large cohort of patients with EM treated with doxycycline in a single centre.

Methods

Patients ≥18 years, with EM defined according to European criteria [16], treated with doxycycline between June 2006 and October 2015 at the University Medical Centre Ljubljana, Slovenia, and who had been included in three prospective treatment trials were eligible for analysis of doxycycline-induced photosensitivity. Patients received oral doxycycline 100 mg twice daily for 10, 14 or 15 days. In each trial, patients were assigned to treatment groups based on arrival order at the clinic so that every second patient received one of the two treatment options being compared in that particular trial. Patients who were prescribed doxycycline were advised to avoid exposure to the sun. Those who were not compliant with following the prescribed treatment regimen or did not attend the 14-day visit were excluded. At baseline and follow-up at 14 days and at 2, 6, and 12 months, patients were examined physically and were asked an open question about health-related symptoms. On day 14, patients were asked an open question about medication compliance and adverse events.

Numerical data were summarized as medians (interquartile range, IQR) and categorical data as frequencies (%) with two-sided 95% confidence intervals (CI) calculated on exact binomial distributions. Two-tailed Fisher exact tests were used for all bivariate comparisons of proportions and Mann–Whitney U test for comparisons of numeric variables. A P value < 0.05 was considered statistically significant.

Results

A total of 864 patients with EM were evaluated. Among these, three patients were excluded from further analysis after antibiotic treatment was discontinued following an allergic reaction, manifested as maculopapular rash a few days after starting therapy. A further three patients were excluded because they did not attend the 14-day visit. All the remaining 858 patients stated compliance with the prescribed treatment regimen.

Overall, 16/858 (1.9, 95% CI 1.1–3.0%) patients reported photosensitivity reactions: 0/108 (0, 95% CI 0–3.4%), 8/488 (1.6, 95% CI 0.7–3.2%), and 8/262 (3.1, 95% CI 1.3–5.9%) of those who received doxycycline for 10, 14 or 15 days, respectively. Photosensitivity reactions presented from June to October with highest frequency in July (Table 2). The clinical symptoms of photosensitivity developed on the fifth day of therapy in one patient and on the tenth day in another, but exact timing of the onset of photosensitivity reactions for remaining 14 patients was not obtained. Photosensitivity reactions ranged from itching and burning sensations without any change in skin colour in seven patients, to mild erythema of sun-exposed face and extremities in nine patients. Of the 16 patients with photosensitivity reactions, 13 did not adhere to the recommendation to avoid sun exposure completely. One patient was deliberately exposed to the sun while sunbathing, but other 12 patients were exposed only during unavoidable daily activities, such as going to work, which did not exceed one hour per day for an individual patient. None of the patients had any sequelae of photosensitivity at the 2-month visit or later. Women were more often affected than men (13/475 [2.7%], 95% CI 1.5–4.6% versus 3/383 [0.8%], 95% CI 0.2–2.3%; P = 0.04). Patients with photosensitivity did not differ from those without photosensitivity according to age (median 43.5 years, IQR 39–55 versus 53 years, IQR 42–62; P = 0.08) or according to use of any concomitant medications (6/16 [37.5%] versus 358/842 [42.5%]; P = 0.80). None of the patients with photosensitivity was taking medications known to be associated with phototoxicity or to potentially interact with doxycycline, however 24/842 (2.9%) patients without photosensitivity were taking potentially phototoxic medications such as thiazides or phenothiazines concomitantly with doxycycline. Photosensitivity occurred more frequently in patients treated with doxycycline for 14 or 15 days (16/750 [2.1%], 95% CI 1.2–3.4%) than in those treated for 10 days (0/108 [0%], 95% CI 0.0–3.4%), but the difference was not significant (P = 0.24). Neither did this difference reach statistical significance when comparing 14-day (8/488 [1.6%], 95% CI 0.7–3.2%) versus 10-day group (P = 0.36) and 15-day (8/262 [1.3–5.9%], 95% CI 1.2–3.4%) versus 10-day group (P = 0.11).
Table 2

Number of patients with erythema migrans and frequency of photosensitivity reactions according to month of enrolment/presentation

Month

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep

Oct

Nov

Dec

Overall

Number of patients

6

0

3

5

26

123

251

178

139

76

34

17

858

Patients (%) with photosensitivity

0

0

0

0

0

3 (2.4%)

10 (4.0%)

0

2 (1.4%)

1 (1.3%)

0

0

16 (1.9%)

Discussion

In the present analysis, 16/858 (1.9%) patients with EM treated with doxycycline experienced photosensitivity reactions. The clinical symptoms of photosensitivity ranged from itching and burning sensations to mild erythema of sun-exposed face and extremities. A particular strength of our study is that we had data on a large number of patients with the same clinical entity who were treated at a single medical centre and given the same instructions, thus avoiding potential confounders when comparing data from different centres not using uniform approaches.

The frequency of doxycycline-induced photosensitivity found in our study is at the lower limit of some earlier reports [5, 710, 13]. The reason for much higher incidence rates (up to 15%) [4, 6, 11] reported in some other studies is not known. It was suggested that higher daily dose of doxycycline (300 mg) used for prolonged time (20 days) may have contributed to the higher frequency of these reactions [3, 4]. However, some other studies with lower daily dosages and shorter treatment duration found similarly high incidence rates of doxycycline-induced photosensitivity [5, 11, 12].

Another possible explanation for the differences encountered could be variations in exposure to the sun. This is supported by the highest frequency of photosensitivity reactions during the July, which is the month with the highest average monthly hours of sunshine in Slovenia. Accordingly, we found that 13/16 patients who developed photosensitivity did not follow the recommendation to avoid sun exposure. However, since we obtained data on sun exposure only in patients who reported photosensitivity but not in those who did not experience this adverse event, we could not evaluate the magnitude of the impact of sun exposure for development of photosensitivity. This is a major limitation of our study. The second limitation of our study is the fact that exact timing of the onset of photosensitivity reactions for the majority of patients experiencing photosensitivity was not obtained.

Interestingly, we observed photosensitivity more frequently in patients treated with doxycycline 100 mg twice daily for 15 days than in those treated for 14 days, and not at all in the 10-day treatment group. However, overlapping 95% CIs suggest that these differences were not significant. This accords with earlier findings that doxycycline-induced photosensitivity might depend on the dose of doxycycline and the intensity of UV-A radiation [17], but is not related to duration of therapy [18].

We found that women were more often affected than men (13/483 [2.7%] versus 3/387 [0.8%]; P = 0.04). It is not clear why in our study the women were affected more often than men. After carefully reviewing previous studies no differences in overall proportion of females were found, however exact data on sex proportion among patients with photosensitivity reactions in these studies were not provided (Table 1). Sex and/or other inherent/genetic characteristics may predispose an individual to photosensitivity. However, data to support this assumption are scarce [19]. Another possibility may be that in our study the women were more frequently exposed to the sun.

The previous studies on doxycycline efficacy in patients with EM did not provide detailed information on clinical symptoms of photosensitivity [314]. In our cohort of patients the clinical symptoms of photosensitivity were mild and had no long-term sequelae which may not always be the case when using doxycycline [15].

When deciding on which of the recommended antibiotics to prescribe for treating a patient with EM, several aspects should be considered: efficacy; drug allergy; adverse effects, including phototoxicity; pharmacokinetic/pharmacodynamic properties; ecological effect on the microbiota; likelihood of co-infection with A. phagocytophilum, which, if suspected would favour the use of doxycycline; and cost. Doxycycline has better central nervous system penetration than other oral antibiotics recommended for treatment of EM and remains the only oral antibiotic with proven favourable treatment outcome in patients with early Lyme neuroborreliosis [2]. Doxycycline may have other advantages over β-lactam antibiotics, such as reduced potential to cause Clostridium difficile infection [20], and is associated with low probability of allergic reactions [21]. In addition, since the antimicrobial spectrum of doxycycline is not limited to Lyme borreliae, observations of this study may support the use of doxycycline in other tick-borne diseases, including rickettsioses [22].

Conclusions

When deciding on antibiotic treatment in adult patients with EM, the potential phototoxicity of doxycycline need not be regarded as a major drawback. This study showed that if patients were advised to restrict exposure to the sun, such adverse events occurred only exceptionally and exhibited no long-term sequelae.

Abbreviations

CI: 

Confidence intervals

EM: 

Erythema migrans

IQR: 

Interquartile range

Declarations

Acknowledgements

Some of the data on the 370 patients have already been reported for other purposes [9, 14].

Funding

This work was supported by the Slovenian Research Agency (grant numbers P3–0296, J3–6788). The funding source had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

MV and DS performed literature search and gathered and analysed the patient data. FS, FFB and DS contributed in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All three studies from which information on doxycycline adverse events was obtained had been approved by the Medical Ethics Committee of the Ministry of Health of the Republic of Slovenia (No. 38/05/06, 36/05/09, and 83/05/10); two of the studies were registered at http://clinicaltrials.gov, Identifiers NCT00910715 and NCT01163994. All participants gave informed consent in written form prior to participation in the studies.

Consent for publication

Not applicable.

Competing interests

Franc Strle is an unpaid member of the steering committee of the ESCMID Study Group on Lyme Borreliosis/ESGBOR. All the other authors report no potential conflicts.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia
(2)
Department of Neurology, University Medical Centre Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia
(3)
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1104 Ljubljana, Slovenia

References

  1. Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet. 2012;379:461–73.View ArticlePubMedGoogle Scholar
  2. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MC, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic Anaplasmosis, and Babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–134.View ArticlePubMedGoogle Scholar
  3. Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995;39:661–7.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992;17:273–80.View ArticleGoogle Scholar
  5. Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, Visintainer P, et al. Duration of antibiotic therapy for early Lyme disease. Ann Intern Med. 2003;138:697–704.View ArticlePubMedGoogle Scholar
  6. Dattwyler RJ. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med. 1997;37:289–94.View ArticleGoogle Scholar
  7. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet. 1990;336:1404–6.View ArticlePubMedGoogle Scholar
  8. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, Johnson RC, et al. Treatment of early Lyme disease. Am J Med. 1992;92:396–403.View ArticlePubMedGoogle Scholar
  9. Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. Am J Med. 2010;123:79–86.View ArticlePubMedGoogle Scholar
  10. Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection. 2000;28:153–6.View ArticlePubMedGoogle Scholar
  11. Strle F, Maraspin V, Lotrič-Furlan S, Ruzić-Sabljić E, Cimperman J. Azithromycin and doxycycline for treatment of Borrelia positive erythema Migrans. Infection. 1996;24:64–8.View ArticlePubMedGoogle Scholar
  12. Strle F, Preac-Mursic V, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection. 1993;21:83–8.View ArticlePubMedGoogle Scholar
  13. Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J Antimicrob Chemother. 1992;30:543–50.View ArticlePubMedGoogle Scholar
  14. Stupica D, Lusa L, Ružić-Sabljić E, Cerar T, Strle F. Treatment of erythema Migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis. 2012;55:343–50.View ArticlePubMedGoogle Scholar
  15. Goetze S, Hiernickel C, Elsner P. Phototoxicity of doxycycline: a systematic review on clinical manifestations, frequency, cofactors, and prevention. Skin Pharmacol Physiol. 2017;30:76–80.View ArticlePubMedGoogle Scholar
  16. Stanek G, Fingerle V, Hunfeld K-P, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17:69–79.View ArticlePubMedGoogle Scholar
  17. Bjellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summer-time. A study on doxycycline and lymecycline in human volunteers , using an objective method for recording erythema. Br J Dermatol. 1994;130:356–60.View ArticlePubMedGoogle Scholar
  18. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline ─ a dose-related phenomenon. Clin Exp Dermatol. 1993;18:425–7.View ArticlePubMedGoogle Scholar
  19. Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol. 2005;5:309–16.View ArticlePubMedGoogle Scholar
  20. Doernberg SB, Winston LG, Deck DH, Chambers HF. Does doxycycline protect against development of Clostridium difficile infection? Clin Infect Dis. 2012;55:615–20.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O. French network of regional centers of Pharmacovigilance. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. Br J Dermatol. 2012;166:1333–41.View ArticlePubMedGoogle Scholar
  22. de Oliveira SV, Guimarães JN, Reckziegel GC, Neves BM, Araújo-Vilges KM, Fonseca LX, et al. An update on the epidemiological situation of spotted fever in Brazil. J Venom Anim Toxins Incl Trop Dis. 2016;22:22. Available at: https://doi.org/10.1186/s40409-016-0077-4 View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement